See related research by Murphy *et al.*, <http://arthritis-research.com/content/13/4/R135>

Much is still not understood regarding mechanisms of osteoarthritis (OA)-related pain. Studies have found differing degrees of association between radiographic changes and pain severity, but it is generally accepted that factors other than radiographic features contribute to pain levels. Damage or inflammation of joint structures such as the synovial capusule, bursae, fat pad, ligaments, menisci, or adjacent bone may contribute to pain severity.

There is increasing recognition of the important role of central pain sensitivity, however, which is the focus of the recent paper by Murphy and colleagues in *ArthritisResearch and Therapy*\[[@B1]\]. The hypothesis is, and there are data to support, that chronic OA-related peripheral pain stimuli may lead to hyperexcitability of pain-transmitting neurons \[[@B2]\]. Studies have shown that patients with OA do experience heightened pain sensitivity, with substantial intra-individual variability \[[@B2],[@B3]\]. However, the vast majority of OA-related treatments target the periphery; for example, nonsteroidal anti-inflammatory drugs act on local inflammatory processes. While these medications also affect central pain mechanisms - either directly or indirectly through their influence on peripheral pain stimuli and sensitivity \[[@B4]\] - failure to more fully address central pain sensitization may be one reason for inadequate pain relief in some patients.

The study by Murphy and colleagues provides additional support that patients differ in the degree to which central mechanisms contribute to OA-related pain and other symptoms \[[@B1]\]. The authors used a cluster analysis approach and identified three subgroups of patients, one of which was characterized not only by the highest pain levels but also by other symptoms characteristic of centrally mediated pain. This is an interesting and clinically relevant approach to the question of central pain contribution, providing support to the notion that patients with greater central pain sensitivity could be identified in routine care settings, without the use of formal pain threshold testing or other processes that would typically be utilized in research.

Given the mounting evidence for the importance of central pain sensitivity in OA \[[@B5]\], how can this be addressed in routine clinical care? There is certainly a need to further educate clinicians (and particularly those in primary care, who typically provide first-line treatment for OA) about the important role of central pain adaptations, basic signs of central pain sensitivity, and the utility of current treatments to address this aspect of pain. Cognitive behavioral pain management interventions have shown efficacy for treating neuropathic pain, but these interventions are underutilized among patients with OA. Increased availability and use of these programs could be one practical step toward improving treatment of the central aspect of pain. Opioid analgesics act centrally and also have a role in OA treatment; despite their potential for adverse side effects, they may be an effective treatment for patients with a strong central contribution to the pain experience. There is also some evidence for use of duloxetine and other antidepressants in the treatment of OA-related pain, and these therapies may be most effective for patients with greater central contributions to pain. More data are needed, however, to determine the appropriateness and effectiveness of these medications in the treatment of OA, as well as guidelines for when and how they are best applied in this patient group.

Murphy and colleagues and other researchers have suggested that OA treatment regimens could be tailored according to patients\' pain mechanisms (for example, relative contribution of peripheral vs. central contributions). This suggestion certainly seems appealing both in terms of clinical efficiency and likelihood of treatment response. However, there are at least two areas in which additional research is needed to support this tailored treatment becoming a clinical reality. First, additional research is needed to both identify new strategies and further evaluate existing therapies (including pharmacological and nonpharmacological) that target central aspects of OA-related pain. This area of treatment development has lagged considerably behind strategies to address peripheral aspects of pain. Second, brief and evidence-based strategies are needed to identify patients who have a stronger central component to OA-related pain. The study by Murphy and colleagues suggests this further research is possible, and other studies - for example, that by Gwilym and colleagues \[[@B6]\] - have used surveys to identify patients with neuropathic pain symptoms. The existing screening tools are probably too cumbersome for busy care providers, however, and simpler methods are needed for clinicians to readily identify patients who may benefit more from treatments that target central pain mechanisms.

In summary, treatment of central pain sensitivity is an area with great promise for improving pain management in at least a subset of patients with OA; efforts are clearly needed to expand the evidence base for both identification and treatment of central pain contributions.
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